BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 19296764)

  • 1. Diabetes and hypertension: which is the best approach?
    Escobar C; Barrios V
    Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):269-71. PubMed ID: 19296764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Anglo-Scandinavian Cardiac Outcomes Trial-- blood pressure lowering arm.
    Coleman JJ; Kendall MJ
    J Clin Pharm Ther; 2006 Aug; 31(4):299-307. PubMed ID: 16882098
    [No Abstract]   [Full Text] [Related]  

  • 3. [The most recent study into blood pressure lowering by amlodipine: the beginning of the end for the beta-blockers].
    van den Meiracker AH; van Montfrans GA
    Ned Tijdschr Geneeskd; 2006 Apr; 150(16):886-8. PubMed ID: 16686086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive therapy and the benefits of atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm extension.
    Sever PS; Poulter NR; Dahlof B; Wedel H;
    J Hypertens; 2009 May; 27(5):947-54. PubMed ID: 19318984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prevention of cardiovascular events by the antihypertensive treatment using amlodipine and perindopril in comparison with the use of atenolol and bendroflumethiazide. The ASCOT (Anglo-Scandinavian Outcomes Trail: blood pressure lowering arm) study results--multicentre, randomised, controlled trial. Landmark in the development of opinions on combination therapy in hypertension? (comment)].
    Widimský J
    Vnitr Lek; 2005 Dec; 51(12):1394-6, 1398-9. PubMed ID: 16430107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).
    Poulter NR; Dobson JE; Sever PS; Dahlöf B; Wedel H; Campbell NR;
    J Am Coll Cardiol; 2009 Sep; 54(13):1154-61. PubMed ID: 19761936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of amlodipine-based therapy among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA).
    Collier DJ; Poulter NR; Dahlöf B; Sever PS; Wedel H; Buch J; Caulfield MJ;
    J Hypertens; 2011 Mar; 29(3):583-91. PubMed ID: 21297503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.
    Williams B; Lacy PS; Thom SM; Cruickshank K; Stanton A; Collier D; Hughes AD; Thurston H; O'Rourke M; ; ;
    Circulation; 2006 Mar; 113(9):1213-25. PubMed ID: 16476843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-pill amlodipine/atorvastatin helps patients of diverse ethnicity attain recommended goals for blood pressure and lipids (the Gemini-AALA study).
    Erdine S; Ro YM; Tse HF; Howes LG; Aguilar-Salinas CA; Chaves H; Guindy R; Chopra P; Moller RA; Schou IM;
    J Hum Hypertens; 2009 Mar; 23(3):196-210. PubMed ID: 18800143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.
    Ostergren J; Poulter NR; Sever PS; Dahlöf B; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E;
    J Hypertens; 2008 Nov; 26(11):2103-11. PubMed ID: 18854748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.
    Sever P; Dahlöf B; Poulter N; Wedel H; Beevers G; Caulfield M; Collins R; Kjeldsen S; Kristinsson A; McInnes G; Mehlsen J; Nieminem M; O'Brien E; Ostergren J;
    Eur Heart J; 2006 Dec; 27(24):2982-8. PubMed ID: 17145722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
    Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
    J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication.
    Gupta AK; Dahlof B; Dobson J; Sever PS; Wedel H; Poulter NR;
    Diabetes Care; 2008 May; 31(5):982-8. PubMed ID: 18235048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implications of the ADVANCE study for clinical practice.
    Zannad F
    J Hypertens Suppl; 2008 Sep; 26(3):S29-32. PubMed ID: 19363850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evidence-based treatment of hypertension in type 2-diabetes. New studies support active blood pressure reduction].
    Nilsson P
    Lakartidningen; 2000 Feb; 97(6):568-72. PubMed ID: 10707481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of ASCOT-BPLA: antihypertensive treatment with an amlodipine-based regimen is cost effective compared with an atenolol-based regimen.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Heart; 2008 Feb; 94(2):e4. PubMed ID: 17916665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
    Fogari R; Zoppi A; Mugellini A; Corradi L; Lazzari P; Preti P; Derosa G
    J Cardiovasc Pharmacol; 2008 Mar; 51(3):217-22. PubMed ID: 18356684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How early should blood pressure control be achieved for optimal cardiovascular outcomes?
    Weir MR; Zappe D; Orloski LA; Sowers JR
    J Hum Hypertens; 2011 Apr; 25(4):211-7. PubMed ID: 20596060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial.
    Gupta AK; Poulter NR; Dobson J; Eldridge S; Cappuccio FP; Caulfield M; Collier D; Cruickshank JK; Sever PS; Feder G;
    Am J Hypertens; 2010 Sep; 23(9):1023-30. PubMed ID: 20725056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of isolated systolic hypertension in diabetes mellitus type 2.
    Os I; Gudmundsdottir H; Kjeldsen SE; Oparil S
    Diabetes Obes Metab; 2006 Jul; 8(4):381-7. PubMed ID: 16776744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.